Evorpacept (ALX148) for Metastatic Cancers

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Massachusetts General Hospital, Boston, MA
Metastatic Cancers+5 More
Evorpacept (ALX148) - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a drug called evorpacept can be safely given to people with cancer.

See full description

Eligible Conditions

  • Metastatic Cancers
  • Tumors, Solid
  • Cancer, Advanced
  • Non-Hodgkin's Lymphoma (NHL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Metastatic Cancers

Study Objectives

This trial is evaluating whether Evorpacept (ALX148) will improve 1 primary outcome in patients with Metastatic Cancers. Measurement will happen over the course of Up to 28 days.

Up to 28 days
Dose-limiting toxicities (Number of participants with a DLT)

Trial Safety

Safety Progress

1 of 3

Other trials for Metastatic Cancers

Trial Design

6 Treatment Groups

Evorpacept (ALX148) + Pembrolizumab + 5FU + Platinum
1 of 6
Evorpacept (ALX148) + Trastuzumab + Ramucirumab + Paclitaxel
1 of 6
Evorpacept (ALX148) + Pembrolizumab
1 of 6
Evorpacept (ALX148)
1 of 6
Evorpacept (ALX148) + Trastuzumab
1 of 6
Evorpacept (ALX148) + Rituximab
1 of 6
Experimental Treatment

This trial requires 174 total participants across 6 different treatment groups

This trial involves 6 different treatments. Evorpacept (ALX148) is the primary treatment being studied. Participants will be divided into 6 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Evorpacept (ALX148) + Pembrolizumab + 5FU + PlatinumThe Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.
Evorpacept (ALX148) + Trastuzumab + Ramucirumab + PaclitaxelThe Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.
Evorpacept (ALX148) + PembrolizumabThe Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.
Evorpacept (ALX148)
Drug
The Part 1 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks.
Evorpacept (ALX148) + TrastuzumabThe Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.
Evorpacept (ALX148) + RituximabThe Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with rituximab infusions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trastuzumab
FDA approved
Rituximab
FDA approved
Pembrolizumab
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 28 days
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 28 days for reporting.

Closest Location

Massachusetts General Hospital - Boston, MA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Metastatic Cancers or one of the other 5 conditions listed above. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available..
Adequate Bone Marrow Function.
Adequate Renal & Liver Function.
Adequate Performance Status

Patient Q&A Section

What is lymphoma, diffuse?

"Diffuse large B-cell lymphoma is the most common lymphoma encountered in older people. Typically the disease arises in one of 3 sites: the central nervous system (40%), mediastinum (22%) and other extranodal sites (24%)." - Anonymous Online Contributor

Unverified Answer

Can lymphoma, diffuse be cured?

"Findings from a recent study series, it was not possible to observe complete remission or a cure in patients with lymphoma or lymphomas of histologies other than diffuse large B cell lymphoma and mycosis fungoides. We think that in most patients with DLBCL the disease will slowly disappear without the need of repeated, prolonged, intensive, and frequently painful and time-consuming chemotherapy. However, in some patients with DLBCL and the bulky follicular type, a cure might be achieved." - Anonymous Online Contributor

Unverified Answer

How many people get lymphoma, diffuse a year in the United States?

"The incidence of DLBCL and MCL among all races were similar around the country, while there were important racial disparities in the incidence of low grade and diffuse grade DLBLC." - Anonymous Online Contributor

Unverified Answer

What are the signs of lymphoma, diffuse?

"Anorexia and weight loss, fever, night sweats, peripheral neuropathy can all be signs of lymphoma, diffuse. An abdominal mass, enlarged lymph nodes and blood in urine are possible signs of lymphoma, diffuse." - Anonymous Online Contributor

Unverified Answer

What causes lymphoma, diffuse?

"The primary causes of lymphoma remain unknown. Multiple hypotheses have been proposed for its pathogenesis, including genetic, virus, and environmental factors. In particular, the possibility that autoimmune disease is an important etiologic link between lymphoma and inflammatory bowel disease remains untested." - Anonymous Online Contributor

Unverified Answer

What are common treatments for lymphoma, diffuse?

"Many types of lymphoma respond to chemotherapy or radiotherapy alone. However, many types of lymphoma respond well to combination chemotherapy and radiotherapy. Because of its high morbidity and mortality, radiation therapy is generally not recommended except in highly selected situations where chemotherapy does not work to control disease. The treatment of lymphoma depends on the type of lymphoma, the stage of disease, and the extent of the person's illness." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets lymphoma, diffuse?

"The mean age of people with lymphoma, diffuse was 60.3 years old. The greatest age group was 35 to 64 years old. The mean age of women was a little old, 62.7 years old compared to 59.8 years old for men at the time of diagnosis, and the greatest aged group was 40 to 64 years old. The lowest aged group was 20 to 34 years old (30.9% of people), and the greatest aged group was 90 to 94 years old (12.3% of people). Overall, people with diffuse lymphoma at the time of diagnosis had a male to female ratio of 1.0." - Anonymous Online Contributor

Unverified Answer

What is evorpacept (alx148)?

"Alx148 is an immune checkpoint targeting molecule that reverses key tumor suppressor pathways. In preclinical studies, Alx148 exhibited safety and antitumor effects in diverse tumor models. In a phase 1 study in patients with solid and hematological malignancies, it resulted in an immunomodulatory response and clinical activity in patients with multiple myeloma and lymphoma. In September 2017, Alx148 was approved by [U.S. Food and Drug Administration (FDA)] to treat patients with relapsed and refractory non-small-cell lung cancer (NSCLC)." - Anonymous Online Contributor

Unverified Answer

Is evorpacept (alx148) safe for people?

"The most common side effects were nausea and insomnia, which were transient. The most common side effects were headache, dizziness, dyspnoea and asthenia, which were mostly mild to moderate in severity. The most serious side effect was hypersensitivity, which was observed a few patients, often because they had underlying medical disease. It is uncertain whether the most common side effects were related to alx148." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating lymphoma, diffuse?

"Lymphoma remains challenging and continues to challenge the medical community. The research efforts now are centered on more effective agents combined with the use of innovative clinical approaches that target particular populations with a high risk of developing aggressive disease." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for lymphoma, diffuse?

"Clinical trial decisions for relapsed DLBCL are impacted by clinician preference, patient preference, and comorbidity. Better approaches to addressing comorbidity, incorporating health-related quality of life measures into the management of lymphoma, and improving communication between clinicians may improve enrollment and outcomes of clinical trials in this group. Further prospective investigation is warranted." - Anonymous Online Contributor

Unverified Answer

How quickly does lymphoma, diffuse spread?

"The average interval of the time from the development of lymphoma until the diagnosis of spread has a great influence on prognosis. In a recent study, findings indicates that when lymphoma, diffuse, spreads on average 12 months after its appearance, the prognostic value is similar to that when the disease is less advanced. Therefore, spread of lymphoma, diffuse, should be assessed by imaging-detected metastases only when other indicators of disease progress have become evident." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Metastatic Cancers by sharing your contact details with the study coordinator.